This is to inform you that Outcome of the Board Meeting of the Company held on today i.e. Thursday 14th May 2026 in accordance with SEBl (Listing Obligations and Disclosures Requirements) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shree Ganesh Biotech reported audited standalone financial results for FY ended March 31, 2026. Revenue from operations surged 362% to Rs. 2,295.76 lakhs from Rs. 497.05 lakhs year-on-year. However, profitability declined significantly: PBT fell 25% to Rs. 38.69 lakhs and PAT dropped 26% to Rs. 27.84 lakhs. Total expenses increased sharply to Rs. 2,401.16 lakhs (vs Rs. 592.86 lakhs), primarily driven by material costs of Rs. 2,264.10 lakhs. The statutory auditor issued an Unmodified Opinion (clean audit). The company operates in a single segment with minimal cash reserves (Rs. 0.97 lakhs) despite having substantial loans and investments.
Revenue growth of 362% is offset by cost escalation and profit decline, indicating margin pressure. Shareholders may be concerned about rising expenses outpacing revenue and minimal cash position despite large revenue scale.